Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 3, 2014, Pages 1114-1119

  Lui, Vivian Wai Yan ^a   Peyser, Noah D ^a   Ng, Patrick Kwok Shing ^b   Hritz, Jozef ^a,c   Zeng, Yan ^a   Lu, Yiling ^b   Li, Hua ^a   Wang, Lin ^a   Gilbert, Breean R ^a   General, Ignacio J ^a   Bahar, Ivet ^a   Ju, Zhenlin ^b   Wang, Zhenghe ^d   Pendleton, Kelsey P ^a   Xiao, Xiao ^a   Du, Yu ^a   Vries, John K ^a   Hammerman, Peter S ^e   Garraway, Levi A ^e   Mills, Gordon B ^b   Johnson, Daniel E ^a   Grandis, Jennifer R ^a   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MASARYK UNIVERSITY   (Czech Republic)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Driver mutations; Phosphatase mutations; Stat3 activation

Indexed keywords

MUTANT PROTEIN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; STAT3 PROTEIN;

ARTICLE; BINDING SITE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EXOME; GENE MUTATION; GENE SEQUENCE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MOUSE; MUTATION RATE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; UPREGULATION;

DRIVER MUTATIONS; PHOSPHATASE MUTATIONS; STAT3 ACTIVATION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTER SIMULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEOME; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84892928970     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1319551111     Document Type: Article

References (24)

1. Groesser L, et al. (2012) Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 44(7):783-787.
2. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500.
3. Julien SG, Dubé N, Hardy S, Tremblay ML (2011) Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11(1):35-49.
4. Lui VW, et al. (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3(7):761-769.
5. Gao SP, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117(12):3846-3856.
6. Zhang X, et al. (2007) Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci USA 104(10):4060-4064.
7. Veeriah S, et al. (2009) The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 106(23):9435-9440.
8. Barr AJ, et al. (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136(2):352-363.
9. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234(3):779-815.
10. Wang Z, et al. (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304(5674):1164-1166.
11. Lim SH, et al. (2009) Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn. EMBO J 28(22):3564-3578.
12. Stransky N, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333(6046):1157-1160.
13. Chen Y, et al. (2013) STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer 16(1):40-49.
14. Macha MA, et al. (2011) Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck 33(4):482-489.
15. Kusaba T, et al. (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15(6):1445-1451.
16. Scott A, Wang Z (2011) Tumour suppressor function of protein tyrosine phosphatase receptor-T. Biosci Rep 31(5):303-307.
17. Yu J, et al. (2008) Tumor-derived extracellular mutations of PTPRT/PTPrho are defective in cell adhesion. Mol Cancer Res 6(7):1106-1113.
18. Solomon DA, et al. (2008) Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 68(24):10300-10306.
19. Cheung AK, et al. (2008) Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res 68(19):8137-8145.
20. Ruivenkamp CA, et al. (2002) Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet 31(3):295-300.
21. Korff S, et al. (2008) Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability. BMC Cancer 8:329.
22. Dymock BW, See CS (2013) Inhibitors of JAK2 and JAK3: An update on the patent literature 2010-2012. Expert Opin Ther Pat 23(4):449-501.
23. Nallar SC, et al. (2013) Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3(STAT3) activity and promote oncogenesis. J Biol Chem 288 (11):7930-7941.
24. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404.